New insights into the activities and toxicities of the old anticancer drug doxorubicin - van der
Zanden - … Sabina Y. van der Zanden and Xiaohang Qiao contributed equally to this work. …

Cancer immunotherapy has proven remarkably successful through instigation of systemic
antitumor T cell responses. Despite this achievement, further advancements are needed to …

The nuclear envelope (NE) is central to the architecture of eukaryotic cells, both as a physical
barrier separating the nucleus from the cytoplasm and as gatekeeper of selective transport …

The anthracycline doxorubicin (Doxo) and its analogs daunorubicin (Daun), epirubicin (Epi),
and idarubicin (Ida) have been cornerstones of anticancer therapy for nearly five decades. …

The topoisomerase II poisons doxorubicin and etoposide constitute longstanding cornerstones
of chemotherapy. Despite their extensive clinical use, many patients do not respond to …

The endolysosomal system fulfils a myriad of cellular functions predicated on regulated
membrane identity progressions, collectively termed maturation. Mature or “late” endosomes are …

Anthracycline anticancer drugs doxorubicin and aclarubicin have been used in the clinic for
several decades to treat various cancers. Although closely related structures, their molecular …

Proteasome inhibitors are established therapeutic agents for the treatment of hematological
cancers, as are anthracyclines such as doxorubicin. We here present a new drug targeting …

Anthracyclines are effective drugs in the treatment of various cancers, but their use comes
with severe side effects. The archetypal anthracycline drug, doxorubicin, displays two …

Simple Summary Cancer patients, particularly with glioblastoma (GBM), are at increased
risk for thrombosis. This risk is further increased upon treatment with chemotherapy. Tissue …